Cantargia AB | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
1,496.30
16,659.50
24,512.00
34,841.00
269,781.00
Total Accounts Receivable
709.50
432.00
842.00
795.00
1,345.00
Other Current Assets
13.50
196.60
-
1,417.00
370.00
Total Current Assets
2,219.30
17,288.10
25,354.00
37,053.00
271,496.00
Total Investments and Advances
-
394.30
1,747.00
2,662.00
2,957.00
Intangible Assets
1,770.40
2,446.70
4,282.00
-
-
Total Assets
3,989.80
20,129.10
31,383.00
39,715.00
274,453.00
Accounts Payable
698.60
1,407.20
1,794.00
7,419.00
20,619.00
Income Tax Payable
-
-
51.00
186.00
377.00
Other Current Liabilities
159.40
14,624.50
1,313.00
2,075.00
7,337.00
Total Current Liabilities
858.10
16,031.70
3,158.00
9,680.00
28,333.00
Provision for Risks & Charges
-
-
170.00
-
-
Total Liabilities
858.10
16,031.70
3,328.00
9,680.00
28,333.00
Common Equity (Total)
3,131.70
4,097.40
28,055.00
30,035.00
246,120.00
Total Shareholders' Equity
3,131.70
4,097.40
28,055.00
30,035.00
246,120.00
Total Equity
3,131.70
4,097.40
28,055.00
30,035.00
246,120.00
Liabilities & Shareholders' Equity
3,989.80
20,129.10
31,383.00
39,715.00
274,453.00

About Cantargia AB

View Profile
Address
Medicon Village
Lund SN 223 81
Sweden
Employees -
Website http://www.cantargia.com
Updated 09/14/2018
Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. It focuses on the development of CAN04 for the treatment of non-small cell lung cancer and pancreatic cancer. The company was founded by Thoas Michael Fioretos, Kjell Torsten Sjostrom, and Marcus Jaras on October 26, 2009 and is headquartered in Lund, Sweden.